Home/Filings/4/0001209191-22-038696
4//SEC Filing

Gladstone Michael 4

Accession 0001209191-22-038696

CIK 0001845337other

Filed

Jun 21, 8:00 PM ET

Accepted

Jun 22, 4:47 PM ET

Size

9.5 KB

Accession

0001209191-22-038696

Insider Transaction Report

Form 4
Period: 2022-06-17
Transactions
  • Purchase

    Common Stock

    2022-06-17$15.00/sh+766,667$11,500,005766,667 total(indirect: See Footnote)
Footnotes (1)
  • [F1]The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any.

Issuer

Day One Biopharmaceuticals, Inc.

CIK 0001845337

Entity typeother

Related Parties

1
  • filerCIK 0001864256

Filing Metadata

Form type
4
Filed
Jun 21, 8:00 PM ET
Accepted
Jun 22, 4:47 PM ET
Size
9.5 KB